W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Slides:

Advertisements

Similar presentations

W. R. Eric Jamieson, MD, Clifton T. P. Lewis, MD, Marc P

Advertisements

Transcatheter aortic valve replacement in patients with severe aortic stenosis who are at high risk for surgical complications: Summary assessment of.

Max B. Mitchell, MD The Journal of Thoracic and Cardiovascular Surgery

Of mice and men and surgical transcatheter aortic valve insertion

Twenty-Five Year Experience With the St

The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

Aortic valve replacement in low-flow, low-gradient aortic stenosis: Left ventricular ejection fraction matters Victor Dayan, MD, PhD, Philippe Pibarot,

Influence of the On-X mechanical prosthesis on intermediate-term major thromboembolism and hemorrhage: A prospective multicenter study Vincent Chan,

Endoscopic Robotic Mitral Valve Surgery

Fate of aortic bioprostheses: An 18-year experience

Usefulness of microsimulation to translate valve performance into patient outcome: Patient prognosis after aortic valve replacement with the Carpentier–Edwards.

Prospective randomized comparison of CarboMedics and St

Bigger valve size is not always better

When is the Ross operation a good option to treat aortic valve disease? Tirone E. David, MD, Anna Woo, MD, Susan Armstrong, MSc, Manjula Maganti, MSc

George J. Reul, M. D. , Denton A. Cooley, M. D. , J. Michael Duncan, M

Long-term follow-up after aortic valve replacement with Edwards Prima Plus stentless bioprostheses in patients younger than 60 years of age Torsten Christ,

W. R. Eric Jamieson, MD, Guy J. Fradet, MD, James G

The fate of small-size pericardial heart valve prostheses in an older patient population Ruggero De Paulis, MD, Salvatore D'Aleo, MD, Alessandro Bellisario,

Reoperative “valve-in-valve” transapical transcatheter mitral valve replacement in a high-risk patient with a recent transapical transcatheter aortic.

Long-Term Outcomes of the Mosaic Bioprosthesis

Early degeneration of the St Jude Medical Trifecta bioprosthetic aortic valve: A problem of the leaflets or of the stent? Giuseppe Santarpino, MD, Steffen.

Bicuspid aortic valve aortopathy: One size fits all?

Jennifer S. Lawton, MD, Nader Moazami, MD, Michael K

Long-term results of aortic valve–sparing operations in patients with Marfan syndrome Tirone E. David, MD, Sue Armstrong, BSc, Manjula Maganti, BSc, Jack.

Risk-corrected impact of mechanical versus bioprosthetic valves on long-term mortality after aortic valve replacement Ole Lund, MD, PhD, Martin Bland,

The St Jude Medical Trifecta aortic pericardial valve: Results from a global, multicenter, prospective clinical study Joseph E. Bavaria, MD, Nimesh D.

Expanding left ventricular assist device use to patients with disabilities: The role of assistive technology Juan A. Crestanello, MD The Journal of.

The variability of the mitral valve anatomy and terminology

Does the degree of preoperative mitral regurgitation predict survival or the need for mitral valve repair or replacement in patients with anomalous origin.

Long-term evaluation of biological versus mechanical prosthesis use at reoperative aortic valve replacement Vincent Chan, MD, MPH, B-Khanh Lam, MD, MPH,

Quality of mitral valve surgery at the United States Department of Veterans Affairs Juan A. Crestanello, MD The Journal of Thoracic and Cardiovascular.

Transcatheter aortic valve replacement in intermediate-risk patients

Structural deterioration of the Freestyle aortic valve: Mode of presentation and mechanisms Siamak Mohammadi, MD, Richard Baillot, MD, Pierre Voisine,

Aortic valve replacement with the Mitroflow pericardial bioprosthesis: Durability results up to 21 years Charles A. Yankah, MD, PhD, Miralem Pasic, MD,

Michele Gallo, MD, Gino Gerosa, MD

Stentless biological valved conduit for aortic root replacement: Initial experience with the Shelhigh BioConduit model NR-2000C Abdullah Kaya, MD, Robin.

Twenty-year experience with the St Jude Medical mechanical valve prosthesis John S Ikonomidis, MD, PhD, John M Kratz, MD, Arthur J Crumbley, MD, Martha.

Intermediate results of isolated mitral valve replacement with a Biocor porcine valve Giulio Rizzoli, MD, Tomaso Bottio, MD, PhD, Vladimiro Vida, MD,

The aortic valve–sparing operation

Fifteen years of experience with ATS mechanical heart valve prostheses

Surgery for aortic and mitral valve disease in the United States: A trend of change in surgical practice between 1998 and 2005 Scott D. Barnett, PhD,

Kevin Bridge, MD, MSPH, Robert Saeid Farivar, MD, PhD

Tirone E. David, MD, Gheorghe Gavra, MD, Christopher M

Vivek Rao, MD, PhD, Carolyn M. David, BN

Fenton H. McCarthy, MD, MS, Nimesh D. Desai, MD, PhD

David valve-sparing aortic root replacement: Equivalent mid-term outcome for different valve types with or without connective tissue disorder John-Peder.

Replicating the success of mitral valve repair in the aortic valve

The CarboMedics supra-annular Top Hat valve improves long-term left ventricular mass regression Victor X. Mosquera, MD, PhD, Alberto Bouzas-Mosquera,

Bradley G. Leshnower, MD, Robert A. Guyton, MD, Richard J

Marc Licker, MD, John Diaper, RA

Thirty-year experience with a bileaflet mechanical valve prosthesis

St Jude Medical Regent valve

Commentary: Bioprosthetic aortic valve replacement: A high standard of comparison for transcatheter aortic valve implantation Aaron Martin, MD, Michael.

Hemodynamics and early clinical performance of the St

Warfarin or aspirin after mitral valve repair: Why work harder?

Younger age and valve oversizing are predictors of structural valve deterioration after pulmonary valve replacement in patients with tetralogy of Fallot

Hans-Joachim Schäfers, MD

Long-term results of Freestyle stentless bioprosthesis in the aortic position: A single- center prospective cohort of 500 patients Nicolas Amabile, MD,

The Journal of Thoracic and Cardiovascular Surgery

Discussion The Journal of Thoracic and Cardiovascular Surgery

Severe tricuspid or mitral regurgitation in inoperable patients with aortic stenosis. Can we leave them alone? Juan A. Crestanello, MD The Journal of.

Ventricular assistant in restrictive cardiomyopathy: Making the right connection Robert D.B. Jaquiss, MD The Journal of Thoracic and Cardiovascular Surgery

Pasquale Totaro, MD, Vincenzo Argano, MD

Long-term results of the Medtronic Mosaic porcine bioprosthesis in the aortic position Amedeo Anselmi, MD, Erwan Flécher, MD, PhD, Vito Giovanni Ruggieri,

Vinay Badhwar, MD, John S. Ikonomidis, MD, PhD, Jeffrey P. Jacobs, MD

Chordal replacement with polytetrafluoroethylene sutures for mitral valve repair: A 25- year experience Tirone E. David, MD, Susan Armstrong, MSc, Joan.

Durability of pericardial versus porcine bioprosthetic heart valves

Which biologic valve should we select for the 45- to 65-year-old age group requiring aortic valve replacement? F. Dagenais, MD, P. Cartier, MD, P. Voisine,

Thanos Sioris, MD, Tirone E

Paul Philipp Heinisch, MD, Thierry Carrel, MD

Presentation transcript:

St Jude Medical Epic porcine bioprosthesis: Results of the regulatory evaluation W. R. Eric Jamieson, MD, Clifton T.P. Lewis, MD, Marc P. Sakwa, MD, Denton A. Cooley, MD, Vibhu R. Kshettry, MD, Kent W. Jones, MD, Tirone E. David, MD, John A. Sullivan, MD, Guy J. Fradet, MD, David S. Bach, MD The Journal of Thoracic and Cardiovascular Surgery Volume 141, Issue 6, Pages 1449-1454.e2 (June 2011) DOI: 10.1016/j.jtcvs.2010.05.055 Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Figure 1 Freedom from reoperation owing to SVD for AVR by age groups (≤60, 61–70, >70 years). SVD, Structural valve deterioration; AVR, aortic valve replacement. The Journal of Thoracic and Cardiovascular Surgery 2011 141, 1449-1454.e2DOI: (10.1016/j.jtcvs.2010.05.055) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Figure 2 Freedom from reoperation owing to SVD for MVR by age groups (≤60, 61–70, >70 years). SVD, Structural valve deterioration; MVR, mitral valve replacement. The Journal of Thoracic and Cardiovascular Surgery 2011 141, 1449-1454.e2DOI: (10.1016/j.jtcvs.2010.05.055) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Patient survival AVR by age groups (≤60, 61–70, >70 years) Patient survival AVR by age groups (≤60, 61–70, >70 years). AVR, Aortic valve replacement; SE, standard error. The Journal of Thoracic and Cardiovascular Surgery 2011 141, 1449-1454.e2DOI: (10.1016/j.jtcvs.2010.05.055) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Patient survival MVR by age groups (≤60, 61–70, >70 years) Patient survival MVR by age groups (≤60, 61–70, >70 years). MVR, Mitral valve replacement; SE, standard error. The Journal of Thoracic and Cardiovascular Surgery 2011 141, 1449-1454.e2DOI: (10.1016/j.jtcvs.2010.05.055) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Hemodynamics—aortic valve replacement (mean gradients and effective orifice areas) at 6 months and 2 years. The Journal of Thoracic and Cardiovascular Surgery 2011 141, 1449-1454.e2DOI: (10.1016/j.jtcvs.2010.05.055) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Hemodynamics—mitral valve replacement (mean gradients and effective orifice areas) at 6 months and 2 years. The Journal of Thoracic and Cardiovascular Surgery 2011 141, 1449-1454.e2DOI: (10.1016/j.jtcvs.2010.05.055) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions

Left ventricular (LV) mass regression. The Journal of Thoracic and Cardiovascular Surgery 2011 141, 1449-1454.e2DOI: (10.1016/j.jtcvs.2010.05.055) Copyright © 2011 The American Association for Thoracic Surgery Terms and Conditions